News|Articles|March 28, 2014

PTSM: Pharmaceutical Technology Sourcing and Management

  • PTSM: Pharmaceutical Technology Sourcing and Management-04-02-2014
  • Volume 10
  • Issue 4

Covance Expands Global Biologics Capabilities

Author(s)Melanie Sena

Covance adds workspace and scientists to biologics team in Indianapolis facility.

Covance, a drug development services company, reported the expansion of large molecule bioanalytical space and the addition of new members to its biologics team.

The additional space will be added at its central laboratory facility in Indianapolis, Ind. The expansion, which is planned to open during the second half of 2014, will double the company’s large molecule capacity and is expected to add approximately 100 new positions over the next five years.

In addition to the expansion, the company also appointed Mike Holsapple, PhD, as Covance’s executive director of global immunotoxicology. Holsapple is a member of the Academy of Toxicological Sciences and past president of the Society of Toxicology, with more than 30 years of experience.

Source: Covance


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.